Mubadala Bio and Marcyrl Group Sign a Strategic Partnership to Localize Women’s Health, Fertility and Respiratory Therapies in the UAE

The partnership will bring a portfolio of women’s health and fertility medicines to the UAE, supporting women across key stages of reproductive health, from fertility and pregnancy through to childbirth, alongside treatments for common gynecological and hormonal conditions. The respiratory portfolio will address a range of acute and chronic respiratory conditions and includes metered dose inhalers, dry powder inhalers, nebulization solutions and nasal sprays. Together, the two portfolios will be localized and distributed in the UAE, with further products expected to be added over time.

Dr. Essam Mohamed, Group Chief Executive Officer of Mubadala Bio, said: ” Localizing pharmaceutical products is central to building a resilient life sciences ecosystem in the UAE. Women’s health is a priority therapy area for Mubadala Bio and our partnership with Marcyrl, which also includes respiratory medicines, allows us to localize a comprehensive portfolio of products and expand access to important treatments across the UAE.”

Dr. George Saad, Chief Executive Officer of Marcyrl Group said: “This partnership marks an important step in expanding access to essential medicines in the UAE and across the GCC. By combining Marcyrl Group’s manufacturing expertise in women’s health, fertility and respiratory care with Mubadala Bio’s regional platform, we will advance localization, strengthen healthcare resilience and improve patient access to quality treatments.”

The agreement supports Mubadala Bio’s broader efforts to strengthen local pharmaceutical capabilities, expand access to priority therapies, and contribute to an integrated life sciences ecosystem in the UAE.

About Mubadala Bio:

Mubadala Bio is a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. As a catalyst for progress and innovation, we are accelerating the growth of the life sciences ecosystem by enhancing drug security and expanding access to affordable, essential treatments.

Operating through two core verticals, Integrated Biopharma and Pharma Logistics, we are advancing local pharmaceutical manufacturing while ensuring timely access to critical and lifesaving medications. With a growing footprint across the UAE, Asia, Africa, and Europe, we are driving impact both locally and globally.

Our portfolio focuses on key therapy areas that address some of the world’s most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine. Headquartered in Abu Dhabi and wholly owned by Mubadala Investment Company, we are fostering innovation, cultivating local talent, and helping build a knowledge-based economy – delivering better health, closer for all.

About Marcyrl Group:

Founded in 1998 and headquartered in Cairo, Marcyrl Group is one of Egypt’s leading pharmaceutical manufacturers. The Group focuses on specialty generics, with particular strength in hormonal and respiratory therapies and a dedicated focus on women’s health and fertility treatment. Marcyrl develops and produces a broad portfolio of medicines, including products manufactured under license from multinational partners. Marcyrl Group exports to markets across the Middle East and Africa. In 2023, Development Partners International (DPI) and Amethis joined as investors, supporting the Group’s expansion into new therapeutic areas, technology partnerships and international markets.